Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study
✍ Scribed by Linda A. Everse; Ingrid B. Renes; Ina M. Jürgenliemk-Schulz; Derk H. Rutgers; Monique R. Bernsen; Hub F.J. Dullens; Willem Den Otter; Jan J. Battermann
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- French
- Weight
- 58 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Tumor recurrence and outgrowth of metastases limit the therapeutical effect of radiotherapy. We have tested whether these problems can be overcome by supplementing radiotherapy with locoregional interleukin-2 (IL-2) treatment. The SL2 lymphoma and the M8013 mammary carcinoma were used. Mice bearing a 10-day-old s.c. tumor were locally irradiated and were treated daily with IL-2 peritumorally for 5 or 10 days. Low-dose IL-2 therapy improved local response (LR) and increased disease-free survival (DFS) in both tumor models following either single-dose irradiation or fractionated irradiation. For example, 93% of SL2-bearing mice treated with single-dose irradiation and 10 days of IL-2 experienced long-term DFS, compared with 17% for irradiation alone (p F 0.0001). Additionally, treatment of one tumor with irradiation ؉IL-2 led to anti-tumor effects in a second, untreated tumor in 80% of SL2-bearing mice. LR was increased to 100% and DFS to 70% when the second, nonirradiated tumor was also treated with peritumoral IL-2. We conclude that supplementing local radiotherapy with low doses of IL-2 results in increased local tumor control and regression of distant, non-irradiated tumors. This type of radioimmunotherapy is a promising new approach for the clinic. Int.